ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
After market 05:30:00 am | |||
| 757.7 USD | -0.30% |
|
755 | -0.36% |
| 10:45am | Wegovy weight loss sustained for four years in trial, Novo Nordisk says | RE |
| 10:03am | Foreign investment in Germany reaches new record | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
757.7
USD
Average target price
850.4
USD
Spread / Average Target
+12.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.98% | 68TCr | |
| +31.69% | 59TCr | |
| -3.52% | 36TCr | |
| +18.59% | 33TCr | |
| +4.07% | 28TCr | |
| +16.51% | 24TCr | |
| +9.39% | 21TCr | |
| -8.83% | 20TCr | |
| +7.09% | 17TCr | |
| -1.22% | 16TCr |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- BofA Securities Raises Price Target on Eli Lilly to $800 From $750, Maintains Buy Rating